NCT02145988 - DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

July 31, 2018

Conditions

DiabetesPeripheral Arterial Disease

Interventions

DRUG

DLBS1033

Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period

DRUG

Placebo

Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period

Trial Locations (2)

Unknown

Department of Internal Medicine, Faculty of Medicine, University of Udayana/Sanglah Hospital, Denpasar

Department of Internal Medicine, RSUD Wangaya, Denpasar